Peringatan Keamanan

Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Oral rat LD50 is over 20,000 mg/kg while intravenous rat LD50 is over 7,000 mg/kg.

Cefotaxime

DB00493

small molecule approved

Deskripsi

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).

Struktur Molekul 2D

Berat 455.465
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 1 hour.
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Rapidly absorbed following intramuscular injection.

Metabolisme

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite. The desacetyl metabolite has been shown to contribute to the bactericidal activity. Two other urinary metabolites (M2 and M3) account for about 20-25%. They lack bactericidal activity.

Rute Eliminasi

Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.

Interaksi Obat

906 Data
Probenecid The serum concentration of Cefotaxime can be increased when it is combined with Probenecid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cefotaxime.
Tenofovir disoproxil Cefotaxime may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Cefotaxime may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Cefotaxime may increase the nephrotoxic activities of Tenofovir.
Succinic acid The excretion of Succinic acid can be decreased when combined with Cefotaxime.
Citrulline The excretion of Citrulline can be decreased when combined with Cefotaxime.
Pravastatin The excretion of Pravastatin can be decreased when combined with Cefotaxime.
Aminohippuric acid The excretion of Aminohippuric acid can be decreased when combined with Cefotaxime.
Zidovudine The excretion of Zidovudine can be decreased when combined with Cefotaxime.
Cefdinir The excretion of Cefdinir can be decreased when combined with Cefotaxime.
Leucovorin The excretion of Leucovorin can be decreased when combined with Cefotaxime.
Fluorescein The excretion of Fluorescein can be decreased when combined with Cefotaxime.
Hydrocortisone The excretion of Hydrocortisone can be decreased when combined with Cefotaxime.
Quinapril The excretion of Quinapril can be decreased when combined with Cefotaxime.
Dinoprostone The excretion of Dinoprostone can be decreased when combined with Cefotaxime.
Famotidine The excretion of Famotidine can be decreased when combined with Cefotaxime.
Fexofenadine The excretion of Fexofenadine can be decreased when combined with Cefotaxime.
Benzylpenicillin The excretion of Benzylpenicillin can be decreased when combined with Cefotaxime.
Rosuvastatin The excretion of Rosuvastatin can be decreased when combined with Cefotaxime.
Captopril The excretion of Captopril can be decreased when combined with Cefotaxime.
Tazobactam The excretion of Tazobactam can be decreased when combined with Cefotaxime.
Cyclic adenosine monophosphate The excretion of Cyclic adenosine monophosphate can be decreased when combined with Cefotaxime.
Cholic Acid The excretion of Cholic Acid can be decreased when combined with Cefotaxime.
Glutaric Acid The excretion of Glutaric Acid can be decreased when combined with Cefotaxime.
Oxalic Acid The excretion of Oxalic Acid can be decreased when combined with Cefotaxime.
Taurocholic acid The excretion of Taurocholic acid can be decreased when combined with Cefotaxime.
Ellagic acid The excretion of Ellagic acid can be decreased when combined with Cefotaxime.
Avibactam The excretion of Avibactam can be decreased when combined with Cefotaxime.
Eluxadoline The excretion of Eluxadoline can be decreased when combined with Cefotaxime.
Silibinin The excretion of Silibinin can be decreased when combined with Cefotaxime.
Relebactam The excretion of Relebactam can be decreased when combined with Cefotaxime.
Oseltamivir The excretion of Oseltamivir can be decreased when combined with Cefotaxime.
Conjugated estrogens The excretion of Conjugated estrogens can be decreased when combined with Cefotaxime.
Piperacillin The excretion of Piperacillin can be decreased when combined with Cefotaxime.
Trifluridine The excretion of Trifluridine can be decreased when combined with Cefotaxime.
Allopurinol The excretion of Allopurinol can be decreased when combined with Cefotaxime.
Cimetidine The excretion of Cimetidine can be decreased when combined with Cefotaxime.
Methotrexate The excretion of Methotrexate can be decreased when combined with Cefotaxime.
Cephalexin The excretion of Cephalexin can be decreased when combined with Cefotaxime.
Valaciclovir The excretion of Valaciclovir can be decreased when combined with Cefotaxime.
Levocarnitine The excretion of Levocarnitine can be decreased when combined with Cefotaxime.
Tetracycline The excretion of Tetracycline can be decreased when combined with Cefotaxime.
Estradiol The excretion of Estradiol can be decreased when combined with Cefotaxime.
Acyclovir The excretion of Acyclovir can be decreased when combined with Cefotaxime.
Cefaclor The excretion of Cefaclor can be decreased when combined with Cefotaxime.
Ranitidine The excretion of Ranitidine can be decreased when combined with Cefotaxime.
Bumetanide The excretion of Bumetanide can be decreased when combined with Cefotaxime.
Sitagliptin The excretion of Sitagliptin can be decreased when combined with Cefotaxime.
Ceftibuten The excretion of Ceftibuten can be decreased when combined with Cefotaxime.
Doripenem The excretion of Doripenem can be decreased when combined with Cefotaxime.
Saxagliptin The excretion of Saxagliptin can be decreased when combined with Cefotaxime.
Baricitinib The serum concentration of Baricitinib can be increased when it is combined with Cefotaxime.
Dexamethasone The excretion of Dexamethasone can be decreased when combined with Cefotaxime.
Oxytetracycline The excretion of Oxytetracycline can be decreased when combined with Cefotaxime.
Polythiazide The excretion of Polythiazide can be decreased when combined with Cefotaxime.
Prednisolone phosphate The excretion of Prednisolone phosphate can be decreased when combined with Cefotaxime.
Dexamethasone acetate The excretion of Dexamethasone acetate can be decreased when combined with Cefotaxime.
Acamprosate The excretion of Acamprosate can be decreased when combined with Cefotaxime.
Cyclosporine The risk or severity of nephrotoxicity can be increased when Cyclosporine is combined with Cefotaxime.
Icosapent The risk or severity of nephrotoxicity can be increased when Icosapent is combined with Cefotaxime.
Cefotiam The excretion of Cefotiam can be decreased when combined with Cefotaxime.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotaxime.
Cefmenoxime The risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Cefotaxime.
Cefmetazole The risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Cefotaxime.
Indomethacin The excretion of Indomethacin can be decreased when combined with Cefotaxime.
Triamterene The risk or severity of nephrotoxicity can be increased when Triamterene is combined with Cefotaxime.
Cefpiramide The risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Cefotaxime.
Loracarbef The risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Cefotaxime.
Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Cefotaxime.
Nabumetone The risk or severity of nephrotoxicity can be increased when Nabumetone is combined with Cefotaxime.
Ketorolac The risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Cefotaxime.
Tenoxicam The risk or severity of nephrotoxicity can be increased when Tenoxicam is combined with Cefotaxime.
Celecoxib The risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Cefotaxime.
Tolmetin The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tolmetin.
Rofecoxib The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Rofecoxib.
Fenoprofen The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Fenoprofen.
Valdecoxib The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Valdecoxib.
Diclofenac The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Diclofenac.
Sulindac The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulindac.
Bacitracin The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Bacitracin.
Amphotericin B The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Amphotericin B.
Cephaloglycin The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cephaloglycin.
Adefovir dipivoxil The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Adefovir dipivoxil.
Pentamidine The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Pentamidine.
Mefenamic acid The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Mefenamic acid.
Naproxen The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Naproxen.
Sulfasalazine The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulfasalazine.
Phenylbutazone The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Phenylbutazone.
Meloxicam The risk or severity of methemoglobinemia can be increased when Cefotaxime is combined with Meloxicam.
Carprofen The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Carprofen.
Tacrolimus The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Tacrolimus.
Etacrynic acid The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Etacrynic acid.
Ceforanide The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Ceforanide.
Salicylic acid The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Salicylic acid.
Acetylsalicylic acid The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Acetylsalicylic acid.
Hydrochlorothiazide The excretion of Hydrochlorothiazide can be decreased when combined with Cefotaxime.
Balsalazide The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Balsalazide.
Cefditoren The risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Cefditoren.

Target Protein

Penicillin-binding protein 1b pbp1b
Penicillin-binding protein 2a pbp2a
Penicillin-binding protein 3 pbpC
Penicillin-binding protein 1A pbpA
Penicillin-binding protein 2B penA
Solute carrier family 22 member 6 SLC22A6
Organic anion transporter 3 SLC22A8
Solute carrier family 22 member 11 SLC22A11
Solute carrier family 22 member 7 SLC22A7
Solute carrier family 15 member 1 SLC15A1
Albumin ALB
Beta-lactamase
Solute carrier family 15 member 2 SLC15A2

Referensi & Sumber

Synthesis reference: Ingolf Macher, Gerhard Widschwenter, "Production of cefotaxime and new sodium salts." U.S. Patent US5831086, issued May, 1992.

Contoh Produk & Brand

Produk: 63 • International brands: 5
Produk
  • Cefotaxime
    Injection, powder, for solution • 500 mg/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 1 g/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 2 g/1mL • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 500 mg/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 1 g/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 2 g/1 • Intramuscular; Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 10 g/1 • Intravenous • US • Generic • Approved
  • Cefotaxime
    Injection, powder, for solution • 500 mg/1 • Intramuscular; Intravenous • US • Generic • Approved
Menampilkan 8 dari 63 produk.
International Brands
  • Rantaksym — Ranbaxy
  • Raxim — Ranbaxy
  • Spinocef — Abbott
  • Sporim — Pharmacare
  • Talcef — Ipca

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul